Biomarker Disease Diagnosis Targeted by Thermo Fisher Scientific and Immunodiagnostik Collaboration
Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis
Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis.
The collaboration seeks to further biomarker research, by combining the antibody-based detection technology developed by Immunodiagnostik with the liquid–chromatrography tandem mass spectrometry (LC–MS–MS) analytical technology from Thermo Scientific. The companies hope to enable the development of assays specifically for the diagnosis of cardiovascular disease and bone metabolism disorders. Furthermore, Immunodiagnostik will utilize its academic and clinical network connections to allow the validation of developed assays.
“We are impressed with Immundiagnostik’s antibody expertise, and are confident that the immunoaffinity-purification of proteins will take quantitative LC–MS–MS protein analysis to the next level,” said Jeff Zonderman, Thermo Fisher director of clinical and toxicology LC–MS.
For more information please visit:ref=http://www.thermofisher.com>www.thermofisher.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
